Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGI-0301 Plus Sorafenib in Advanced Hepatocellular Carcinoma
NCT06309485Phase 2Recruiting
- Sponsor
- Haichang Biotech
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Modified DNA Oligonucleotides, Lipid-based Nanoparticles, Single-strand DNA
- Countries
- 2
01
Overview
A Phase 2 trial of WGI-0301 in hepatocellular carcinoma (HCC), sponsored by Haichang Biotech. Started Jul 2024; status: recruiting.
02
Drugs
WGI-0301
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06309485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309485.